Boult Wade Tennant
/es

Archivos: Boletines

julio 25, 2023

Emson v. Hozelock: Public prior use and a “mere paper proposal”

On 8 July 2020, the Court of Appeal issued its decision in the Emson v. Hozelock case ([2020] EWCA Civ 871). The

julio 24, 2023

Plant Breeders Rights – action required on Retained EU Plant Variety Rights in the UK.

Following the UK’s exit from the European Union (EU), Retained EU Plant Variety Rights were awarded to provide continuing protection in the

julio 13, 2023

G1/23 – A burdensome new referral to the EPO’s Enlarged Board regarding the state of the art.

Can a product be simultaneously available and unavailable to the public? In T 0438/19 , the Board grappled with questions regarding the criteria

The EPO’s guidelines and machine learning.

The EPO has published its Guidelines to provide guidance on various proceedings before the EPO, such as for the search and examination

julio 10, 2023

The CJEU rules against second medical use SPCs

On 9 July 2020 the Court of Justice of the European Union (CJEU) handed down its decision in Case C-673/18, a referral

junio 23, 2023

Proposals for reform of the EU’s SPC system.

On 27 April 2023 the European Commission published proposals concerning supplementary protection certificates (SPCs) for medicinal products and plant protection products. SPC protection

mayo 11, 2023

2023 Changes to the EPO Guidelines – Section F-IV, 3.4 – Inconsistencies

Background One of the more unique, and often debated, aspects of prosecution before the EPO is the requirement that the description and

abril 26, 2023

EPO Notice regarding the 10 day rule

The EPO have published further information in a Notice in the Official Journal dated 6 March 2023 in preparation for the abolition

abril 23, 2023

Return of the Big Mac: EUIPO Board of Appeal flips decision of Cancellation Division

In 2019, the EUIPO’s Cancellation Division raised some eyebrows in the trade marks world when they revoked in full the BIG MAC

marzo 31, 2023

New CJEU Referral requesting clarification of the term “human embryo” for patent purposes.

The patenting of inventions relating to human embryonic stem cells remains a controversial topic in Europe.